Conditioning With Alkylating Agents Prior to Transplant for Myelofibrosis
Patients with myelofibrosis conditioned with 2 alkylating agents may have better transplant outcomes compared with patients receiving 1 alkylating agent.
Primary Myelofibrosis
Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Homozygous JAK2 Germline Haplotype May Be Linked to Worse Survival in Myelofibrosis
Researchers expanded on a previous study showing that the JAK2 46/1 haplotype was associated with decreased survival in primary myelofibrosis.
Phenotypic Predictors for Long-Term Survival in Primary Myelofibrosis
For some patients with primary myelofibrosis, the decision to undergo early transplant may depend on long-term survival predictions.
- Loading...
Loading...
Next post in Uncategorized
Loading... 
Loading...